RxDoctor Payments Data

Raffay Khan, MD

Clinical Cardiac Electrophysiology · Schaumburg, ILNPI 1194052829

Payments from drug & device makers

$1,046in general payments, 2019–2025

Across 40 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$300
  • Biosense Webster, Inc.$118
  • Edwards Lifesciences$115
  • Chiesi USA, Inc.$92
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$82
  • Novartis$61
  • plus $278 from 7 others

What the payments were for

  • Food & beverage$95491%
  • Education$162%
  • Gifts$757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,046 in reported general payments places this provider in the 0th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

See all clinical cardiac electrophysiology providers in Illinois

Medicare billing

Part B allowed, 2024
$681,537
Medicare patients
733
Services billed
3,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$210,408
EntrestoSacubitril/Valsartan54$61,309
JardianceEmpagliflozin37$36,946
XareltoRivaroxaban19$20,386
Metoprolol Succinate188$3,369
Amlodipine Besylate164$1,375
Carvedilol139$1,314
Metoprolol Tartrate165$1,133
Midodrine Hcl21$1,042
Amiodarone Hcl58$1,037
Atorvastatin Calcium99$970
Lisinopril78$886
Hydralazine Hcl72$851
Flecainide Acetate28$709
SotalolSotalol Hcl37$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$61$61,30954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 158 clinical cardiac electrophysiology providers in Illinois.

Other clinical cardiac electrophysiology in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →